Vasomune is very pleased to announce that the company has received a substantial investment on behalf of the Government of Canada through the National Research Council (NRC) for Vasomune’s continued development of AV-001, the company’s lead candidate drug targeting COVID-19.

Through this investment, Vasomune, as a Canadian clinical-stage biopharmaceutical company based in downtown Toronto, will continue on with its clinical trial program evaluating AV-001 treatment in patients with severe-to-moderate COVID-19 disease.

The Government of Canada’s recognition of the merit of AV-001 during the COVID-19 pandemic is highly valued and will facilitate the further development of what could be a mainstay of COVID-19 treatment for Canadians as well as patients around the world in the future.

Read more here.